Robyn Hartvickson, MD
Family Medicine · Newton, KSNPI 1679532659
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,502 of the $6,740 with a category attached, or 81.6%. 30 manufacturers reported payments, led by Modernatx, Inc. at 24.0% of the total. Reporting peaked in 2023 at $2,574 and has fallen 68.4% since, to $814 in 2025. Among family medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- AbbVie$1K
- Pfizer$723
- Amgen$436
- Lilly USA, LLC$407
- Astellas Pharma US Inc$277
- plus $2K from 24 others
Across 604 payments — averaging $3320.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$843K
- Novavax Inc$330K
- Merck$305K
- GSK$171K
- Sanofi Pasteur Inc.$138K
- Pfizer$108K
- plus $111K from 2 others
What the payments were for
- Travel & lodging$1,22418%
- Food & beverage$5,50282%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 4 | $1,619 |
| AbbVie(2 entities) | 88 | $1,306 |
| Pfizer | 57 | $723 |
| Amgen | 26 | $436 |
| Lilly USA, LLC | 29 | $407 |
| Astellas Pharma US Inc | 18 | $277 |
| AstraZeneca | 14 | $253 |
| Novo Nordisk | 15 | $233 |
| Bayer | 15 | $217 |
| Merck | 12 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $131 |
| Biohaven Pharmaceuticals, Inc. | 7 | $130 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| Novartis | 5 | $77 |
| Eisai Inc. | 4 | $75 |
| Daiichi Sankyo Inc. | 5 | $74 |
| Boehringer Ingelheim | 4 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Abbott | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Amarin Pharma, Inc. | 3 | $46 |
| Exact Sciences | 3 | $42 |
| Pacira Therapeutics, Inc. | 2 | $41 |
| Johnson & Johnson | 3 | $39 |
| GSK | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$6,740 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $64,673 |
| MounjaroTirzepatide | 36 | $37,221 |
| OzempicSemaglutide | 24 | $32,496 |
| JardianceEmpagliflozin | 37 | $28,005 |
| XareltoRivaroxaban | 27 | $18,565 |
| RybelsusSemaglutide | 11 | $18,384 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,648 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 42 | $13,447 |
| FarxigaDapagliflozin Propanediol | 14 | $10,223 |
| MyrbetriqMirabegron | 15 | $7,644 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,073 |
| VascepaIcosapent Ethyl | 13 | $6,003 |
| Bupropion XlBupropion Hcl | 45 | $2,573 |
| Levothyroxine Sodium | 406 | $2,513 |
| Gabapentin | 214 | $2,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $723 | $78,120106 claims |
| Novo NordiskOzempic, Rybelsus | $233 | $50,88035 claims |
| Lilly USA, LLCMounjaro | $407 | $37,22136 claims |
| Boehringer IngelheimJardiance | $62 | $28,00537 claims |
| Johnson & JohnsonXarelto | $39 | $18,56527 claims |
| AstraZenecaFarxiga | $253 | $10,22314 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $7,64415 claims |
| GSKAnoro Ellipta | $37 | $6,07313 claims |
| AbbVieSynthroid | $1,306 | $1,87027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Newton
- Richard GloverNewton$14K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.